FDA Provides EUA for COVID-19 Treatment

On November 9, the United States Food and Drug Administration issued an emergency use authorization (EUA) to bamlanivimab for the treatment of mild-to-moderate COVID-19. The monoclonal antibody therapy is authorized for COVID-19 patients who are age 12 and older, who weigh at least 88 pounds, and who are at high risk of severe COVID-19 and/or hospitalization. This includes patients who are older than 65 and those with preexisting systemic health problems. Clinical trials demonstrated that bamlanivimab reduced COVID-19-related hospitalization or emergency department visits in patients at high risk for disease progression compared to a placebo. Additional research is needed, however, to fully establish safety and efficacy. Read more here.